Humanetics Corporation
Humanetics Corporation is a clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing and commercializing products to enhance human health and wellbeing. Founded in 1988, the company specializes in radiation modulators, adjunctive oncology therapies, and pulmonary protective therapies, particularly for COVID-19. Humanetics is known for its lead drug candidate, BIO 300, which is being developed as a radioprotectant for military and civilian use, as well as a treatment to improve outcomes in cancer patients receiving radiotherapy. The company is actively engaged in research programs for non-small cell lung cancer, prostate cancer, and head and neck cancers.
Humanetics Corporation
What We Do
BIO 300 is a new class of drug focused on improving outcomes in cancer patients receiving radiotherapy. It acts as a radioprotectant, protecting normal tissues from radiation damage while potentially sensitizing tumors to radiotherapy. It is also being developed as a medical countermeasure to prevent radiation damage in military and civilian populations. Nonclinical studies confirm that BIO 300 can protect normal tissue from radiation, while acting additively with radiation to kill tumors.
Application Area
Show More (6)Infectious Diseases
Psychological and Cognitive Health and Performance
Digital Health Technologies
Show More (1)Services
Key People
President and CEO
Chief Medical Officer
Vice President of Research and Development
Director of Chemistry, Manufacturing and Controls
Director
Director
News & Updates
Humanetics has selected Lifecore Biomedical to provide CDMO services supporting the development of BIO 300 for the prevention of Acute Radiation Syndrome.
Humanetics announced positive results from a Phase 2 clinical trial in a COVID-19 study aimed at improving pulmonary function.
Humanetics secured additional funding to advance the development of its drug to prevent radiation injury.
Humanetics advances the development of a novel radiation protection drug with new study results.
Humanetics presented at the 2024 Department of Defense Scientific Meeting.
Humanetics will participate in the BIO Investor Forum in San Francisco to discuss its lead drug candidate, BIO 300.
The Uniformed Services University awarded a grant to support continued collaboration with Humanetics to develop a radiation countermeasure.
Humanetics will present at the BIO International Convention in San Diego.
Humanetics presented at the Oppenheimer 34th Annual Healthcare Life Science Conference.
Humanetics announced it will present at several investor and partnering conferences in February 2024.
Major General (Ret.) Barbara R. Holcomb joined the board at Humanetics, bringing extensive experience in nursing, healthcare, and medical research.
Dr. Colin Chinn was appointed as Chief Medical Officer at Humanetics.
Humanetics published positive clinical trial results of BIO 300 in patients with non-small cell lung cancer.
Humanetics received funding to study BIO 300 as a treatment for idiopathic pulmonary fibrosis.
Humanetics was awarded a contract from the Department of Defense to develop the first FDA-approved drug to prevent radiation injury.
BIO 300 was featured at the Military Health System Research Symposium, highlighting its development as a medical countermeasure for acute radiation syndrome.
BIO 300 was shown to enhance the efficacy of radiotherapy against lung tumors in a nonclinical model.
Humanetics announced positive results from an independent data monitoring committee review of a Phase 2 trial in COVID-19 patients.
BIO 300 demonstrated protection against radiation-induced lung injury.
Humanetics was awarded a patent for its lead drug candidate, BIO 300, developed as a prophylactic treatment to protect against radiation exposure.